Document is current
Any future updates will be listed below
-
Authors
Yang, Annie
Zhang, Zhifang
Chaurasiya, Shyambabu
Park, Anthony K https://orcid.org/0000-0001-7692-8874
Jung, Audrey
Lu, Jianming
Kim, Sang-In
Priceman, Saul https://orcid.org/0000-0002-8136-2112
Fong, Yuman
Woo, Yanghee https://orcid.org/0000-0002-6676-0593
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05346484 at ClinicalTrials.govnct05081492 at ClinicalTrials.govDocuments that mention this clinical trial
730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0730
Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.
https://doi.org/10.1200/jco.2024.42.3_suppl.749
Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases
https://doi.org/10.1136/jitc-2022-006280
Documents that mention this clinical trial
Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases
https://doi.org/10.1136/jitc-2022-006280
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (Department of Defense Idea Award, CA180425)
City of Hope (Department of Surgery Start-Up Grant - N/A)
- License Information
